CoChat

A multicenter characterization of hepatitis associated with immune checkpoint inhibitors

Open access
Patrinely, J. Randall, McGuigan, Ben, Chandra, Sunandana, Fenton, Sarah E., Chowdhary, Akansha, Kennedy, Lucy B., Mooradian, Meghan J., Palmeri, Marisa, Portal, Daniella, Horst, Sara N., Scoville, Elizabeth A., Long, Georgina V., Shi, Chanjuan, Mehnert, Janice M., Sullivan, Ryan J., Salama, April K., Sosman, Jeffrey A., Menzies, Alexander M., Johnson, Douglas B. · 2021 · OncoImmunology
Cited by 64

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Immune checkpoint inhibitors (ICI) predispose patients to immune-related adverse events (irAEs). Although hepatitis is a potentially lethal toxicity, the timing and outcomes have not been well described. In this retrospective study, patients from six international institutions were included if they were treated with ICIs and developed immune-related hepatitis. Patient and tumor characteristics, and hepatitis management and outcomes were evaluated. Of the 164 patients included, most were male (53.7%) with a median age of 63.0 years. Most patients had melanoma (83.5%) and stage IV disease (86.0%). Median follow-up was 585 days; median OS and PFS were not reached. The initial grade of hepatitis was most often grade 2 (30.5%) or 3 (45.7%) with a median time to onset of 61 days. Patients were most commonly asymptomatic (46.2%), but flu-like symptoms, including fatigue/anorexia (17.1%), nausea/emesis (14.0%), abdominal/back pain (11.6%), and arthralgias/myalgias (8.5%) occurred. Most patients received glucocorticoids (92.1%); the median time to improvement by one grade was 13.0 days, and the median time to complete resolution was 52.0 days. Second-line immunosuppression was required in 37 patients (22.6%), and steroid-dose re-escalation in 45 patients (27.4%). Five patients (3%) died of ICI-hepatitis or complications of hepatitis treatment. Ninety-one patients (58.6%) did not resume ICI; of 66 patients (40 grade 1/2, 26 grade 3/4) that were rechallenged, only 25.8% (n = 17) had recurrence. In this multi-institutional cohort, immune-related hepatitis was associated with excellent outcomes but frequently required therapy discontinuation, high-dose steroids, and second-line immunosuppression. Rechallenge was associated with a modest rate of hepatitis recurrence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/2162402x.2021.1875639

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 64

Metadata

Authors
Patrinely, J. R., McGuigan, B., Chandra, S., Fenton, S. E., Chowdhary, A., Kennedy, L. B., Mooradian, M. J., Palmeri, M., Portal, D., Horst, S. N., Scoville, E. A., Long, G. V., Shi, C., Mehnert, J. M., Sullivan, R. J., Salama, A. K., Sosman, J. A., Menzies, A. M., & Johnson, D. B.
Venue
OncoImmunology
Published
2021-01
Volume
10
Issue
1
Pages
1875639-1875639
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W3128367530
Cited by
64
References
17
FWCI
3.51
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. https://app.cochat.ai/papers/10.1080/2162402x.2021.1875639
The paper
Patrinely, J. R., McGuigan, B., Chandra, S., Fenton, S. E., Chowdhary, A., Kennedy, L. B., Mooradian, M. J., Palmeri, M., Portal, D., Horst, S. N., Scoville, E. A., Long, G. V., Shi, C., Mehnert, J. M., Sullivan, R. J., Salama, A. K., Sosman, J. A., Menzies, A. M., & Johnson, D. B. (2021). A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. OncoImmunology. https://doi.org/10.1080/2162402x.2021.1875639

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.